Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $13,317.75 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 29,595 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $0.45, for a total transaction of $13,317.75. Following the sale, the director directly owned 512,525 shares of the company’s stock, valued at $230,636.25. This represents a 5.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $12,494.58.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08.
• On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.48, for a total transaction of $38,808.96.
• On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $31,936.50.
• On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $39,341.25.
• On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total transaction of $15,282.54.
• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total transaction of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $28,336.50.

Werewolf Therapeutics Trading Down 8.8%

Shares of Werewolf Therapeutics stock opened at $0.39 on Friday. The company has a fifty day moving average price of $0.71 and a 200 day moving average price of $0.73. Werewolf Therapeutics, Inc. has a twelve month low of $0.39 and a twelve month high of $2.38. The stock has a market cap of $19.07 million, a price-to-earnings ratio of -0.32 and a beta of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. Analysts forecast that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOWL has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $3.75.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at about $409,000. Renaissance Technologies LLC raised its stake in shares of Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after purchasing an additional 221,766 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Werewolf Therapeutics in the 3rd quarter valued at about $304,000. Vanguard Group Inc. raised its stake in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at about $113,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.